o A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination in Subjects with Solid Tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibito.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND EFFICACY OF ADP-A2M4CD8 IN HLA-A2+ SUBJECTS WITH IMAGE-A4 POSITIVE TUMORS
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o Phase I/IIa Study in Patients with CLDN6-positive solid tumors
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1 First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants with Advanced Malignant Tumors PIQ follow up
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1/2 Study of BMS-986449 with and without Nivolumab or Nivolumab and Ipilimumab.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking OATP inhibitor.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate the safety of GEN1053 as monotherapy and as combination therapy in subjects with malignant solid tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase I Dose Escalation Study of OMX0407 a Salt-inducible Kinase inhibitor in patients with previously treated unresectable solid tumours.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1 Study of JNJ-78278343, a T Cell Redirecting Agent Targeting Human Kallikrein-2 (KLK2), for Advanced Prostate Cancer.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1, open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, in patients with therapy refractory metastatic castration resistant prostate cancer.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas..
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o AN OPEN LABEL, MULTICENTER, DOSEESCALATION, PHASE 1 STUDY TO EVALUATE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1, open-label, multicenter, safety study of SAR442720 in combination with pembrolizumab in patients with advanced malignancies.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1/1b open-label, first-in-human, single agent, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR443216 in participants with relapsed/refractory HER2 expressing solid tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o An open-label, multicenter Phase 1/2 dose escalation and expansion study of THOR-707 as a single agent and as a combination therapy in adult subjects with advanced or metastatic solid tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1 Study of SGN-B6A in Advanced Solid Tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF SINGLE-AGENT PRS-344/S095012 IN PATIENTS WITH SOLID TUMOR.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity ofTNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 (MAGE-A1-Directed TCR-Transduced Autologous CD8+ T-cells) in Patients with HLA-A*02:01 Genotype and Advanced-Stage/Metastatic, MAGE-A1+Solid Tumors that Either Have No Further Approved Therapeutic Alternative(s) or are in a Non-Curable State and Have Received a Minimum of Two Lines of Systemic Therapy.
Investigador Principal: Dr. Emiliano Calvo
Mas información aquí
o A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o Phase 1/1b Open-label, Multicenter Study.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o Phase II Study in Patients with advanced NSCLC, mCRPC, advanced Solid Tumors.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients with Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Radiotherapy with or without Temozolomide and in Recurrent Glioblastoma as Single Agent.
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OFPF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITHRELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC),CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULARLYMPHOMA (FL).
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o An Open-Label, Multicenter, Pharmacokinetic Study of Lurbinectedin in Patients with Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY‑4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MORPHEUS-LUNG)
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II
PLATFORM TRIAL
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA (MORPHEUS-MELANOMA
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Phase Ib/II, open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of MuLtiple Treatment Combinations in Patients with breast cancer (Morpheus‑breast cancer)
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A PHASE Ib/II, OPEN-LABEL, MULTICENTER,RANDOMIZED UMBRELLA STUDY EVALUATINGTHE EFFICACY AND SAFETY OF MULTIPLEIMMUNOTHERAPY-BASED TREATMENTCOMBINATIONS IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC UROTHELIALCARCINOMA AFTER FAILURE WITHPLATINUM-CONTAINING CHEMOTHERAPY(MORPHEUS-mUC)
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors Site Pre-Study Visit Follow-Up Letter
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (zalifrelimab) Administered Intravesically as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer (NMIBC).
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcRIIB), in Combination with Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma that has Relapsed or is Refractory to Rituximab
Investigador Principal: Dra. Irene Moreno
Mas información aquí
o A first-in-human dose-escalation and expansion study with the SIRPadirected monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive Bcell Non-Hodgkin Lymphoma (NHL)
Investigador Principal: Dr. Pérez de Oteyza
Mas información aquí
o An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies.
Investigador Principal: Dr. Pérez de Oteyza
Mas información aquí
o A Phase 1 First in Human Study of the Menin-MLL (KMT2A) Inhibitor
Investigador Principal: Dr. Pérez de Oteyza
Mas información aquí
o This is a phase 1b study of the combination of REGN5458 and standard of care regimens in relapsed/refractory myeloma.
Investigador Principal: Dr. Pérez de Oteyza
Mas información aquí
o A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562
Investigador Principal: Dr. Ramón
Mas información aquí
o A First-in-Human, Multi-center, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects with Advanced Solid Tumors
Investigador Principal: Dr. Ramón
Mas información aquí
o Phase 1 FIH study with ABBV-400, an antibody drug conjugate (ADC) consisting of a c-Met targeting antibody conjugated to a potent topoisomerase 1 (Top1) inhibitor payload. This c-Met targeting antibody, is the same antibody on Telisotuzumab vedotin (ABB-V399), which recently received FDA breakthrough status. The FIH study (M21-404) will evaluate patients with solid tumors known to express c-Met with a primary focus in NSCLC and GEA
Investigador Principal: Dra de Miguel
Mas información aquí
o Prospective collection of donor tissue and blood or leukapheresis product from patients with solid tumours to enable development of methods for the manufacturing of clonal neoantigen T cell products (cNeT).
Investigador Principal: Dra de Miguel
Mas información aquí
o An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON)
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT601) Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients (ARTISTRY-3).
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX-818 Alone and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic HER2-Expressing Cancers
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Immunotherapy with or without Carboplatin in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)
Investigador Principal: Dra de Miguel
Mas información aquí
o An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation in patients with advanced cancer harboring an EGFR and/or HER2 mutation
Investigador Principal: Dra de Miguel
Mas información aquí
o LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o A PHASE I, FIRST IN HUMAN, TWO PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT-INHIBITOR IN SUBJECTS WITH ADVANCED STAGE, RELAPSED/REFRACTORY SOLID TUMORS
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1, dose-escalation and expansion study to assess safety and preliminary antitumor activity of Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after previous standard platinum-based therapy
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o A PHASE 1b DOSE ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF FURMONERTINIB IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EGFR OR HER2 MUTATIONS, INCLUDING EXON 20 INSERTION MUTATIONS
Investigador Principal: Dra de Miguel
Mas información aquí
o A PHASE IA/B, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS
Investigador Principal: Dra de Miguel
Mas información aquí
o A PHASE Ia/Ib DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION
Investigador Principal: Dra de Miguel
Mas información aquí
o A phase II, Single-Arm, open label study evaluating the safety and pharmacokinetics of the intravenous fixed-dose combination (IV FDC) of Tiragolumab and Atezolizumab in participants with locally advanced, recurrent or metastatic solid tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects with Malignant Solid Tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (anti-BTLA antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1b/2, open-label, study of amivantamab monotherapy and in combination with chemotherapy in patients with advance metastatic colorectal cancer
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive
Investigador Principal: Dra de Miguel
Mas información aquí
o Multicentre, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumours
Investigador Principal: Dra de Miguel
Mas información aquí
o A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase Ib/II, multicenter, open-label dose escalation and expansion platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase 1/2 study of the highly selective ROS1 inhibitor NUV-520 in patients with advanced NSCLC and other solid tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Investigador Principal: Dra de Miguel
Mas información aquí
o Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients with Selected Advanced Solid Tumors" con código de protocolo: PM534-A-001-22
Investigador Principal: Dra de Miguel
Mas información aquí
o A Phase I Study of REGN6569, an anti-GITR mAb, with cemiplimab in patients with advanced solid tumor malignancies
Investigador Principal: Dra de Miguel
Mas información aquí
o An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Investigador Principal: Dra de Miguel
Mas información aquí
o Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors (MINOTAUR Study
Investigador Principal: Dra de Miguel
Mas información aquí
o A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (INTRINSIC)
Investigador Principal: Dra de Miguel
Mas información aquí
o Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations
Investigador Principal: Dra de Miguel
Mas información aquí